Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer
Lung Neoplasms - Carcinoma, Non-Small-Cell Lung
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Lung Neoplasms
Study Type
Study Phase
Study Design
Time Perspective: Prospective
Overall Status
There is a growing body of evidence that implicates inflammation as a mechanism of disease progression and reduced survival in patients with advanced cancer. Elevated c-reactive protein levels have been shown to be associated with reduced performance status, specific cancer related symptoms and reduced overall survival. C-reactive protein levels are a surrogate for IL-6 expression. IL-6 is part of an inflammatory signature predicting cancer recurrence. VeriStrat® is a multivariate test which measures protein expression related to a host/tumor interaction mediated by inflammation. The investigators hope to examine the relationship between quality of life outcomes per FACT-L survey and correlate them with changes in c-reactive protein levels and the VeriStrat® status. The hypothesis of this study is that the remarkable survival benefit in the Temel study is mediated by reduced inflammation with improvement of symptom control.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Confirmed diagnosis of stage IV non-small cell lung cancer

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

- Able to read and respond to questions in English

Exclusion Criteria:

- Small Cell Lung Cancer
Leo Jenkins Cancer Center
Greenville, North Carolina, United States
Status: Recruiting
Start Date
October 2014
Completion Date
July 2020
Leo W. Jenkins Cancer Center
Leo W. Jenkins Cancer Center
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page